NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

Stock Information for SES AI Corporation Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SES AI Corporation Class A

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.